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Activation of epidermal growth factor receptor is
required for Chlamydia trachomatis development
Achchhe L Patel1†, Xiaofei Chen1†, Scott T Wood1, Elizabeth S Stuart2, Kathleen F Arcaro2, Doris P Molina3,
Snezana Petrovic3, Cristina M Furdui1* and Allen W Tsang1*

Abstract
Background: Chlamydia trachomatis (C. trachomatis) is a clinically significant human pathogen and one of the
leading causative agents of sexually transmitted diseases. As obligate intracellular bacteria, C. trachomatis has evolved
strategies to redirect the host’s signaling and resources for its own survival and propagation. Despite the clinical notoriety
of Chlamydia infections, the molecular interactions between C. trachomatis and its host cell proteins remain elusive.
Results: In this study, we focused on the involvement of the host cell epidermal growth factor receptor (EGFR) in
C. trachomatis attachment and development. A combination of molecular approaches, pharmacological agents and cell
lines were used to demonstrate distinct functional requirements of EGFR in C. trachomatis infection. We show that
C. trachomatis increases the phosphorylation of EGFR and of its downstream effectors PLCγ1, Akt and STAT5. While
both EGFR and platelet-derived growth factor receptor-β (PDGFRβ) are partially involved in bacterial attachment to the
host cell surface, it is only the knockdown of EGFR and not PDGFRβ that affects the formation of C. trachomatis
inclusions in the host cells. Inhibition of EGFR results in small immature inclusions, and prevents C. trachomatis-induced
intracellular calcium mobilization and the assembly of the characteristic F-actin ring at the inclusion periphery. By using
complementary approaches, we demonstrate that the coordinated regulation of both calcium mobilization and F-actin
assembly by EGFR are necessary for maturation of chlamydial inclusion within the host cells. A particularly important
finding of this study is the co-localization of EGFR with the F-actin at the periphery of C. trachomatis inclusion where it
may function to nucleate the assembly of signaling protein complexes for cytoskeletal remodeling required for
C. trachomatis development.
Conclusion: Cumulatively, the data reported here connect the function of EGFR to C. trachomatis attachment and
development in the host cells, and this could lead to new venues for targeting C. trachomatis infections and
associated diseases.

Author summary
C. trachomatis is one of the leading causative agents of
sexually transmitted diseases. As an intracellular pathogen
it has evolved strategies to redirect hosts’ signaling and resources for its own survival and propagation. The recruitment of tyrosine phosphorylated proteins at the site of
entry in the host cell and the requirement of actin
polymerization along the time course of infection are well
documented. However, a function of receptor tyrosine kinases beyond the stages of attachment and entry in the
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host cell has never been reported. The studies presented
here show that expression and phosphorylation of host
cell epidermal growth factor receptor (EGFR) is required
for C. trachomatis development. Most importantly, C. trachomatis can regulate the phosphorylation and intracellular localization of EGFR. Co-localization of EGFR with the
F-actin at the periphery of C. trachomatis inclusion in the
host cells is a particularly exciting and novel finding implicating EGFR in the regulation of actin polymerization
around C. trachomatis inclusions. These studies open the
opportunity to investigate key structural and functional elements in EGFR that are necessary for C. trachomatis development and which could lead to new therapies to
advance the treatment of C. trachomatis infections and associated diseases.

© 2014 Patel et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
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Background
Chlamydia trachomatis (C. trachomatis) is among the
most common sexually transmitted pathogens in the US
and contributes to many conditions, such as pelvic inflammatory disease [1,2], infertility [3], and others [4-6]. C.
trachomatis has a small genome, ~1.0 Mb, and like viruses
(e.g., HPV) depend on the host cell for survival [7-11].
The chlamydial life cycle exhibits two forms that are relevant to chlamydial pathology. The elementary body (EB) is
a ‘spore-like’ infectious form, previously perceived as
metabolically inert but recently shown to display maintenance level of metabolic activity [12,13]. Following internalization into the host cells, EBs initiate the inclusion
formation and transform into metabolically active reticulate bodies (RBs), which then replicate within the inclusion. During the time course of RB replication, the early
inclusions expand and fuse to form the early-mid inclusion, which then further expands into the mid-late inclusion. At this stage the RBs are converted back into EBs
and are then released from the host cells through extrusion or cell lysis [14]. The process of C. trachomatis development from attachment/entry to extrusion/exit, is
regulated by an arsenal of C. trachomatis and host cell
proteins [15]. For example, several groups reported the recruitment of tyrosine-phosphorylated host cell proteins at
the site of C. trachomatis entry into the host cell [16,17]
and the requirement of actin polymerization along the
time course of infection [18]. In accordance with this, previous studies have shown that Chlamydia muridarum (C.
muridarum), a species closely related to C. trachomatis,
induces activation of two host cell surface receptor tyrosine kinases: the fibroblast growth factor receptor (FGFR),
and the platelet derived growth factor receptor β
(PDGFRβ) [19,20]. FGFR and PDGFRβ have been proposed to be important for binding of the chlamydial EBs
to the host cell. Elwell and co-workers have shown that
PDGFRβ is phosphorylated upon C. muridarum infection
and can function as a receptor for bacterial binding to the
host cell. A function for PDGFR activation beyond this
stage was not reported [19]. In an elegant study performed
by Kim et al., it was shown that C. muridarum recruits
FGF2 signaling to enhance infection and bacterial spread
[20]. In this case, FGF2 acts as a bridging molecule between the EBs and the receptor that results in the activation of FGFR and bacterial uptake in the host cells.
The question therefore arises whether some of the other
receptor tyrosine kinases play a similar function in the bacterial uptake or have functions that extend beyond this initial stage of bacterial infection. Of particular interest to our
research is the epidermal growth factor receptor (EGFR),
the activation and overexpression of which has been linked
to malignant transformation and progression of a broad
variety of cancers [21]. With respect to cancer, similar
studies have shown that infection with C. trachomatis may
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contribute to malignant transformation as a co-factor with
HPV or independent of HPV [22,23]. Moreover, Fischer
et al. have shown in clinical studies an association between
EGFR expression and C. trachomatis infection in women
with intraepithelial neoplasia and with invasive carcinoma
of the cervix [24]. The involvement of EGFR in chlamydial
infection has been further shown in Chlamydia pneumoniae (C. pneumoniae), in which the protein Pmp21 binds
to and activates EGFR to facilitate host cell entry [25]. A
function of EGFR beyond entry was however not established. Increased activity of EGFR was also observed in a
number of other infectious diseases. Zhang et al. have
studied the function of host cell EGFR for Pseudomonas
aeruginosa in which they show that, during infection, the
activity of EGFR is enhanced followed by up-regulation of
the downstream PI3K and Erk1/2 pathway [26]. Significant
changes in the levels and activity of host signaling molecules like Akt, Erk1/2 and the downstream Bad protein
during the developmental cycle of Chlamydia have also
been reported [27-29]. Similarly, Swanson et al. have
shown an enhanced Neisseria gonorrhoeae-induced activity
of EGFR, which facilitated the gonococcal invasion [30].
EGFR signaling is also an important regulator of cytoskeleton remodeling in cells [31] and, over the years, several research groups have put forward the significance of
host cytoskeletal rearrangement in the chlamydial development cycle [18,32,33]. Interestingly, EGFR has an Factin binding domain (residues 985–996) [34], that is not
present in PDGFRβ or FGFR. The functional consequence
of the interaction between EGFR and the actin cytoskeleton is complex with recent evidence suggesting a role for
the F-actin organization in EGFR dimer formation and polarized response to growth factor stimulation [35].
Altogether, the evidence brought about by the studies
summarized above has prompted us to investigate the potential significance of host cell EGFR in C. trachomatis development and progression of C. trachomatis-associated
diseases. We provide here the evidence identifying EGFR
signaling as the first host cell receptor pathway required
for C. trachomatis development within the host cell. Our
data show: a) distinct functional requirements of EGFR
versus PDGFR during C. trachomatis infection - we demonstrate that PDGFR is critical only at the step of bacterial
attachment, and that knockdown of EGFR but not PDGFR
impairs development of C. trachomatis inclusions within
the host cell; b) infection with C. trachomatis increases
phosphorylation of EGFR and of its downstream effectors
PLCγ1, Akt and STAT5; c) C. trachomatis infection results
in re-localization of EGFR at the periphery of C. trachomatis inclusion inside the host cell; and d) inhibition of
EGFR results in the formation of a diffuse assembly of Factin at the periphery of incompletely developed inclusions.
Co-localization of EGFR with F-actin at the periphery of
C. trachomatis inclusion is a particularly exciting and novel
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finding implicating EGFR in the regulation of actin
polymerization around C. trachomatis inclusions.

Results
C. trachomatis induces EGFR phosphorylation and
activation of EGFR signaling pathways

To assess the role of EGFR in C. trachomatis development,
we initiated our studies by comparing the chlamydial inclusion formation between isogenic cell lines, MEFs EGFR+/+
(mouse embryonic fibroblasts) and EGFR null MEFs
(MEFs EGFR−/−). Both cell lines were infected with chlamydial EBs and at 24 hours post infection (hpi) the cells
were stained with chlamydial FITC-conjugated antilipopolysaccharide (LPS) mAb as described in the Methods.
Confocal imaging was performed to visualize the development of chlamydial inclusions. Well-developed C. trachomatis inclusions were observed in MEFs EGFR+/+ while in
the MEFs EGFR−/− cells, the inclusions were significantly
smaller in size in comparison to MEFs EGFR+/+ (Figure 1A,
quantification is shown in Figure 2B). These initial results
indicated a role of EGFR in C. trachomatis infection and
prompted us to explore it further. We first examined
whether C. trachomatis could induce EGFR phosphorylation in infected cells. To ensure the results were not
biased by the selection of cell line, both HeLa cells and
MEFs EGFR+/+ were used in these experiments. The MEFs
EGFR+/+ cells were infected with chlamydial EBs and lysed
at different time points ranging from 0.5 hpi to 5 hpi. We
observed a significant 1.8-fold increase in phosphorylation
of Y1173 in EGFR that peaked at 2.5 hpi (P < 0.05)
(Figure 1B and C). Similar results were obtained in HeLa
cells (Figure 1D and E), in which we also observed an increase in PDGFRβ phosphorylation (Figure 1F). We further
analyzed the phosphorylation of EGFR at other tyrosine
residues (Y845, Y992, Y1045 and Y1148). An increased
phosphorylation was observed in C. trachomatis-infected
MEFs EGFR+/+ (2.5 and 5 hpi) at all sites analyzed with the
exception of Y1148 (Figure 1G). The results show that C.
trachomatis can enhance EGFR activity and predicts a
function of EGFR signaling in C. trachomatis infection.
EGFR activation in response to extracellular cues (e.g.,
EGF ligand) is known to activate PI3K/Akt, PLCγ1
(phospholipase Cγ1) and STAT proteins (signal transducers and activators of transcription) [36-38]. To determine
whether C. trachomatis-induced EGFR phosphorylation
can also activate its downstream effector proteins, the
phosphorylation of PLCγ1 (Y783), Akt (S473) and STAT5
(Y694) was monitored in MEFs EGFR+/+ and EGFR−/−
cells infected with chlamydial EBs at time points ranging
from 2.5 hpi to 18 hpi. As shown in Figure 3A and the
quantification in Figure 3B, C. trachomatis infection induced a significant increase in phosphorylation of EGFR
and its downstream targets, PLCγ1, Akt and STAT5 at 2.5,
5 and 10 hpi (P < 0.05). At 18 hpi, the phosphorylation of
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EGFR, Akt and PLCγ1 returned close to the basal level.
Interestingly, the phosphorylation of STAT5 persisted at
18 hpi, presumably due to delayed kinetics or secondary
activation subsequent to primary stimulus, an aspect that
will be investigated in future studies. The EGFR dependence of these phosphorylation events was further confirmed by the experiments in MEFs EGFR−/− cells. Under
these conditions, C. trachomatis infection at the same time
points did not induce an increase in phosphorylation of
PLCγ1, Akt and STAT5 proteins (Figure 3C). Combined
with our previous observation of phenotypically smaller inclusions formed in MEFs EGFR−/− cells (Figure 1A), these
findings led us to hypothesize that activation of an EGFRdependent signaling axis was essential for establishing a
successful C. trachomatis infection. To further confirm that
the activation of these proteins was C. trachomatis- and
EGFR-dependent, we investigated the C. trachomatisinduced activation of PLCγ1, STAT5 and Akt in MEF
EGFR+/+ and HeLa cells using multiple methods of EGFR
inhibition. MEFs EGFR+/+ cells were treated with EGFR
siRNA for 48 h, then infected with C. trachomatis for 2.5 h
and tested for activation of PLCγ1, STAT5 and Akt. Chlamydial infection resulted in increased phosphorylation of
all three proteins in cells treated with control siRNA but
not in cells treated with EGFR siRNA (Figure 4A and B; P
< 0.01). C. trachomatis-induced phosphorylation of EGFR,
PLCγ1, STAT5 and Akt was also inhibited by treatment of
HeLa and MEFs EGFR+/+ with Cetuximab, a monoclonal
antibody that binds to the extracellular domain of EGFR
and specifically blocks EGFR functions (Figure 4C-E).
These studies confirmed EGFR activation as one of the upstream regulatory events in the phosphorylation of PLCγ1,
STAT5 and Akt signaling in C. trachomatis-infected cells.
EGFR is essential for the formation of mature
chlamydial inclusions

Next, we assessed the contribution of EGFR to the formation of C. trachomatis inclusions in HeLa cells and MEFs.
EGFR was inhibited by using Erlotinib, Cetuximab or
EGFR siRNA. Erlotinib is a small molecule inhibitor that
targets the intracellular kinase domain of EGFR, while
Cetuximab blocks the binding of EGF to its cognate receptor and thus blocks receptor activation [39,40]. Effective
inhibition of EGFR phosphorylation by Erlotinib or Cetuximab was confirmed by Western blot (Additional file 1:
Figure S1, and S2, and Figure 4C). Similarly, Western blot
analysis was performed to confirm the depletion of EGFR
protein in HeLa and MEFs treated with EGFR siRNA
(Additional file 1: Figure S3 and Figure 4A). HeLa cells
with or without EGFR inhibition (protein depletion or inhibition of function), were infected with C. trachomatis.
The cells were immunostained using anti-chlamydial LPS
mAb at 24 hpi and analyzed by confocal imaging to quantify the size and number of inclusions. In comparison to
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Figure 1 EGFR is activated by C. trachomatis infection. (A) MEFs EGFR+/+ and MEFs EGFR −/− cells were infected with C. trachomatis (Ct). Note
the small chlamydial inclusions (in apple green) formed in the MEFs EGFR−/− cells in comparison to the inclusions formed in MEFs EGFR+/+ cells.
Red color is the counterstaining of the host cell. (B)-(F) Phosphorylation of EGFR in C. trachomatis-infected cells. Monolayers of MEFs EGFR+/+(B)
and HeLa (D) with and without chlamydial infection were lysed at different hpi as indicated and immunoblotted with antibodies against pY1173-EGFR
and EGFR antibodies. The immunoblots from three independent experiments were quantified for both MEFs (C) and HeLa cells (E) after normalization
with β-actin used as loading control. A significant increase (P < 0.05) in phosphorylation of EGFR in MEFs EGFR+/+(C) and HeLa cells (E) was observed at
2.5 hpi. (F) HeLa cells with and without chlamydial infection were lysed at 2.5 hpi. Two biological replicates were subjected to immunoblotting for
pPDGFRβ (Y751) and β-actin as loading control. An increase in PDGFRβ phosphorylation was observed in C. trachomatis-infected cells compared with
non-infected cells. (G) MEFs EGFR+/+ were infected with C. trachomatis for 2.5 h or 5 h. Western blotting was performed for comparing EGFR
phosphorylation by C. trachomatis at various tyrosine residues. C. trachomatis induced phosphorylation was observed at all sites analyzed with
the exception of Y1148 site.

control (DMSO, IgG or control siRNA treated cells), there
was a significant decrease in both the number and size of
chlamydial inclusions under all treatment conditions (P <
0.01 to P < 0.001; Figure 2A). Use of multiple approaches
to inhibit EGFR discounts the possibility of observing
these results because of an unspecific interaction of the
inhibitors with non-target molecules, a potential caveat

of using pharmacological agents [41]. The decreased
chlamydial infection upon EGFR inhibition was further
confirmed by monitoring the chlamydial Hsp60 using
Western blot analysis (Additional file 1: Figure S4). To
ensure that Erlotinib and Cetuximab treatments did not
affect the viability of chlamydial EBs, we infected HeLa
cells with EBs that were pretreated with Erlotinib or
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(See figure on previous page.)
Figure 2 EGFR is important for bacterial attachment and inclusion development. (A) and (B) Effect of EGFR inhibition on number and size
of inclusions. (A) HeLa cells treated with Erlotinib , Cetuximab, EGFR siRNA or PDGFRβ siRNA were infected with C. trachomatis for 24 h, fixed,
analyzed by confocal microscopy and ImageJ software. Data from three independent experiments are expressed as percentage of total number
of inclusions (black bar) or inclusion size (gray bar) in comparison to the control. (B) MEFs EGFR+/+ and MEFs EGFR−/− were infected and
processed as in (A). Data are from three independent experiments. (C) and (D) Effect of EGFR inhibition on chlamydial attachment and entry into
the host cell. HeLa cells treated with Erlotinib, EGFR siRNA and PDGFRβ siRNA (C) or Cetuximab (D), were infected with C. trachomatis for 2.5 h and
inside out staining was performed to differentially stain both external and internalized C. trachomatis. Data from three independent experiments are
expressed as number of cell-associated bacteria (external + internalized C. trachomatis) and internalized C. trachomatis per infected host cell. (E) and (F)
Levels of chlamydial Hsp60 antigen. HeLa cells treated with Erlotinib, Cetuximab, EGFR siRNA or PDGFRβ siRNA were infected with C. trachomatis for
2.5 h and Western blotting was performed with anti-chlamydial Hsp60 antibody. Quantification of the Western blots is from three independent
experiments. (F). β-actin was used as loading control. (G) and (H) Transmission electron micrographs of HeLa cells infected with C. trachomatis. HeLa
cells treated with Erlotinib (G) and Cetuximab (H) with respective controls, were infected with C. trachomatis for 24 h and fixed for transmission
electron microscopy. Note the typical large inclusions in the control chlamydia infected cells. In cells treated with Erlotinib and Cetuximab the
inclusions are smaller and less mature. Scale Bar = 2 μm.
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chlamydial infection were lysed at 2.5, 5, 10 and 18 hpi. Cell lysates were immunoblotted with antibodies against phosphorylated and total EGFR,
PLCγ1, Akt and STAT5. β-actin was used as loading control. Each phosphorylated protein was first normalized against the total protein and then
the fold increase from –Ct to + Ct was calculated from three independent experiments (B). An increased phosphorylation of EGFR, PLCγ1, Akt and
STAT5 was observed in MEFs EGFR+/+ (P < 0.05) while no change was observed in the MEFs EGFR−/− upon C. trachomatis infection.
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Figure 4 C. trachomatis-induced activation of PLCγ1, STAT5 and Akt is EGFR-dependent. (A) and (B) MEFs EGFR+/+ were treated with
either scrambled (control) or EGFR siRNA and then infected with C. trachomatis. Cells were lysed after 2.5 hpi and immunoblotted with antibodies
against phosphorylated and total PLCγ1, STAT5 and Akt (A). Western blots from three independent experiments were quantified. (B). (C-E) HeLa
and MEFs EGFR+/+ were treated with Cetuximab (an anti-EGFR antibody that blocks the binding of EGF to EGFR thus blocking receptor activation)
followed by C. trachomatis infection. At 2.5 hpi the lysates were immunoblotted with antibodies against phosphorylated and total EGFR, PLCγ1,
STAT5 and Akt (C). Western blots from three independent experiments were quantified for both HeLa (D) and MEFs (E). C. trachomatis-induced
phosphorylation of PLCγ1, STAT5 and Akt was completely or partially abrogated in cells that were either depleted of EGFR (A and B; P < 0.01) or
treated with Cetuximab (C-E; P < 0.05). β-actin was used as loading control.

Cetuximab. At 24 hpi the cells were lysed and blotted
using antibodies against chlamydial Hsp60. The Hsp60
antigen load in the cells infected with drug-treated EBs
was comparable to the infection by the untreated EBs
(Additional file 1: Figure S5), confirming that EGFR

inhibitors did not affect the viability of EBs in these experiments. Additional studies were performed to ensure
that the poor inclusion development was not due to loss
of the host cells’ viability during Erlotinib treatment. The
highest concentration (25 μM) and maximum duration
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(24 h) of Erlotinib treatment did not reduce the viability of
HeLa cells (Additional file 1: Figure S6).
Because we observed PDGFRβ phosphorylation triggered by C. trachomatis infection (Figure 1F) and the role
of PDGFRβ has been established in C. muridarum attachment to host cells [19], we also investigated the formation
of chlamydial inclusions in cells treated with PDGFRβ
siRNA. The depletion of PDGFRβ in HeLa cells treated
with PDGFRβ siRNA was confirmed by Western blot
(Additional file 1: Figure S7). Similar to EGFR, depletion
of PDGFRβ decreased the number of inclusions in host
cells (P < 0.01); however, unlike EGFR, the size of the inclusions was not significantly affected by PDGFRβ siRNA
treatment (Figure 2A and Additional file 2: Figure S13).
These results were further substantiated by experiments
in MEFs EGFR−/− cells, which showed similar results to
the EGFR-inhibited HeLa cells (Figure 2B and Additional
file 1: Figure S8). We then examined the possible role of
EGFR in the bacterial attachment to the cell surface and
its subsequent internalization, during the early stage of
C. trachomatis infection. The PDGFRβ siRNA treated
HeLa cells were included as control in these experiments.
HeLa cells with or without EGFR and PDGFRβ inhibition
were infected with C. trachomatis for 2.5 h and processed
for inside-out staining to differentially quantify external
and internalized bacteria. At 2.5 hpi a significant decrease
in cell-associated bacteria (external and internal) was observed (P < 0.05 to P < 0.001) in both EGFR and PDGFRβ
inhibited cells (Figure 2C and D). Since more than 80% of
the cell-associated bacteria were successfully internalized
into the host cell (Figure 2C and D), these results point to
defects in bacterial attachment to the host cell as a main
cause for the decrease in overall chlamydial internalization.
The results were further confirmed by Western blot analysis of chlamydial Hsp60 (P < 0.001; Figure 2E and F).
The small inclusions formed upon inhibition of EGFR
were examined in detail by transmission electron microscopy experiments. Large inclusions were observed in HeLa
cells infected with C. trachomatis whereas the Erlotinib
and Cetuximab treated HeLa cells contained small inclusions (Figure 2G and H).
To further distinguish between the role of EGFR in bacterial attachment from the growth-associated consequences
during C. trachomatis infection, experiments were performed in which EGFR inhibitor (Erlotinib) was added at
different time points (2.5, 5 and 18 hpi), post bacterial infection. Under all conditions the total time of infection with
C. trachomatis was 24 h. EGFR inhibition after 2.5 and 5
hpi, impaired regular inclusion formation and resulted in
formation of numerous bacterial aggregates (Figure 5B
and C, respectively). On the other hand, EGFR inhibition
at 18 hpi did not significantly affect the inclusion development (Figure 5D). These observations correlate well with
the pattern of EGFR signaling shown in Figure 3A and B.
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The results were further confirmed by Western blot analysis of chlamydial Hsp60. Significantly lower expression
of Hsp60 was noted in cells treated with Erlotinib at 2.5
hpi compared with Erlotinib addition at 18 hpi (cells harvested at 24 hpi, Additional file 1: Figure S9). Together,
the results described above show that EGFR has discrete
functions both at the level of bacterial attachment/internalization and subsequent inclusion development.

EGFR regulates intracellular calcium during C. trachomatis
infection

The electron micrographs of the inclusions formed in
EGFR-inhibited cells (Figure 2G & H) were reminiscent
of previously reported type of inclusions formed upon
inhibition of calcium binding protein calmodulin [42].
Since EGFR is known to regulate cellular calcium response and calcium signaling is pivotal for numerous
bacterial infections [43,44], we next tested whether
EGFR could be involved in C. trachomatis-induced calcium release in host cells. HeLa cells were treated with
control siRNA, EGFR siRNA or PDGFRβ siRNA
followed by C. trachomatis infection. At 2.5 and 5 hpi
cells were analyzed by fluorescence microscopy for intracellular calcium. At 2.5 and 5 hpi, a significant increase
in calcium was observed upon C. trachomatis infection
in control siRNA and PDGFRβ siRNA treated cells but
not in EGFR siRNA treated cells (Figure 6A and B; P <
0.001). In another set of experiments, Erlotinib was
added at 2.5 and 5 hpi and cells were incubated for up
to 24 hpi when they were stained for calcium. A significant drop in calcium signal was observed in C. trachomatis-infected cells that had been treated with Erlotinib
at 2.5 and 5 hpi (Additional file 2: Figure S10). Examination of these results in combination with the observations described in Figure 5, suggest that EGFR-induced
calcium release is necessary for the development of C.
trachomatis inclusions. Next, we mimicked a calcium
deficient environment by treating HeLa cells with the
calcium chelator BAPTA/AM for 1 h followed by C. trachomatis infection for 24 h. A significant decrease in
both inclusion size and number was noted, similar to the
conditions of EGFR inhibition in HeLa cells (Figure 6C).
Impaired inclusion formation was also observed in C. trachomatis-infected cells treated with BAPTA/AM at 2 and
5 hpi (more severe in 2 hpi BAPTA/AM treated cells) compared with the control DMSO treated cells (Figure 6D). Intriguingly, the addition of Ionomycin (a calcium ionophore)
to EGFR siRNA treated cells was not able to rescue the formation of chlamydial inclusion (Additional file 2: Figure
S11). This shows that a coordinated and synchronized regulation of EGFR-dependent calcium release along with other
factors regulated by EGFR are required for formation of inclusions within the host cells. We hypothesized that one of
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Figure 5 EGFR is essential for development of chlamydial inclusion post-bacterial entry. (A-D) HeLa cells were infected with C. trachomatis
for 24 h. In panels B-D, EGFR inhibitor Erlotinib was added at 2.5, 5 and 18 hpi, respectively. Under all conditions the total time for C. trachomatis
infection was 24 h followed by fixing, and processing for confocal microscopy. F-actin was detected with Alexa Fluor 488-phalloidin (green) and
chlamydial inclusions were detected using anti-chlamydial LPS antibody (red). Well-developed C. trachomatis inclusions were observed in the
DMSO treated cells (A) and in cells treated with Erlotinib at 18 hpi (D); while incomplete inclusion development and bacterial aggregates were
observed in cells treated with Erlotinib at 2.5 hpi (B) and 5 hpi (C). F-actin staining of HeLa cells with Erlotinib treatment but without C. trachomatis
infection is shown in Additional file 2: Figure S12. Scale bar - 10 μm.

these factors could be F-actin; the reasoning and experiments to address this hypothesis are described next.
EGFR is essential for F-actin assembly around chlamydial
inclusions

Cytoskeletal elements like F-actin and intermediate filaments have been shown to form a dynamically regulated
scaffold around the chlamydial inclusions [18]. Interestingly, a unique feature of EGFR that is not present in
other receptor tyrosine kinases (e.g., PDGFR or FGFR) is
the presence of an F-actin binding domain involved in the
internalization of activated EGFR [45]. Independent studies
have implicated EGF-induced PLCγ1 activation in both calcium mobilization and cytoskeleton remodeling [31,43,46].
Our results demonstrate EGFR-dependent PLCγ1 activation and calcium mobilization upon C. trachomatis infection (Figures 4 and 6). To examine the role of EGFR in
arrangement of F-actin at the inclusion periphery, HeLa
cells treated with Erlotinib, Cetuximab, and EGFR siRNA
were infected with C. trachomatis for 24 h and processed
for confocal microscopy to visualize the intracellular arrangement of F-actin. We observed formation of a distinct
F-actin ring at the inclusion periphery in C. trachomatis infected control cells (DMSO, control siRNA or IgG control)
(Figure 7A and D). In the EGFR siRNA treated cells, the arrangement of F-actin around the C. trachomatis inclusion
was either diffused or disorganized (Figure 7B). Similar

results were observed in the Erlotinib and Cetuximab
treated HeLa cells (Figure 7C and D), as well as in the
MEFs EGFR−/− cells (Figure 7E).
Since EGFR is an F-actin binding protein, we performed additional experiments to investigate whether
EGFR co-localizes with F-actin ring at the periphery of
inclusion. HeLa cells were infected with C. trachomatis
and at 24 hpi the cells were stained for C. trachomatis
EB, EGFR and F-actin (Figure 8A). Co-localization of
EGFR and F-actin at the periphery of C. trachomatis inclusion was evidenced by overlapping fluorescence signals (Figure 8A, Merge). The normalized mean deviation
product (nMDP) [47] was calculated for each pixel in the
image to identify regions of intense co-localization or exclusion within the image. The resulting nMDP color maps
of the whole cell and the inclusion area (dashed box in
Figure 8A) show areas with co-localization ranging from
moderate to intense, with no areas of exclusion (Figure 8B).
The intensity profile for a cross-section in Figure 8A,
which includes from top left to bottom right (left to right
in the intensity profile plot) shows clear enrichment of
EGFR and F-actin at the periphery of inclusion as well as
the cell membrane (Figure 8C). Quantitative processing of
the image data shown in Figure 8 was performed using a
number of independent algorithms [48], which are described in the legend for Additional file 3: Figures S14S20. Similar analysis was applied to other 7 inclusion areas
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(See figure on previous page.)
Figure 6 EGFR is required for C. trachomatis-induced calcium mobilization. (A) and (B) Calcium mobilization induced by C. trachomatis
infection. HeLa cells treated with control siRNA, EGFR siRNA or PDGFRβ siRNA were infected with C. trachomatis for 2.5 h or 5 h and stained with
Fluo-4 AM for visualization of calcium (Ca2+) by fluorescence microscopy. The fluorescence intensity of calcium staining from three independent
experiments was quantified using ImageJ (B). (C) Inclusion development and organization of F-actin at the chlamydial inclusion periphery. HeLa
cells were pre-treated with BAPTA/AM (a calcium chelator) for 1h followed by infection with C. trachomatis for 24 h, fixed, and processed for
confocal microscopy. Data from three independent experiments were analyzed for number and size of inclusions that were significantly reduced in
BAPTA/AM treated cells (left panel). F-actin was detected with Alexa Fluor 488-phalloidin (green) and chlamydial inclusions were detected using
anti-chlamydial LPS antibody (red) (right panel). Note the diffused assembly of F-actin at the inclusion periphery (arrow). (D) Inclusion development in
post infection BAPTA/AM treated cells. HeLa cells were infected with C. trachomatis for 24 h. BAPTA/AM or control DMSO was added at 2 or 5 hpi.
Under all conditions the total time for C. trachomatis infection was 24 h followed by fixing, and processing for confocal microscopy. F-actin was
detected with Alexa Fluor 488-phalloidin (green) and chlamydial inclusions were detected using anti-C. trachomatis EB antibody (red). Data is representative
of two independent experiments. Note the impaired inclusion development in BAPTA/AM treated cells in comparison to the DMSO treated cells. F-actin
staining for HeLa cells with BAPTA/AM treatment but without C. trachomatis infection is also shown in Additional file 2: Figure S12. Scale bar - 10 μm.

and 8 non-inclusion areas (cells that were not infected
with C. trachomatis) and all five parameters show significant increase of EGFR and F-actin co-localization in inclusion areas compared with non-inclusion areas (p < 0.001,
Figure 8D). Additional representative images and analyses
are shown in Additional file 3: Figures S15-20. Collectively, all quantitative analyses show strong and statistically
significant evidence of co-localization of EGFR and Factin at the periphery of inclusion.

Discussion
As an intracellular pathogen, C. trachomatis has developed an arsenal of molecular tools that enables it to hijack signaling and metabolic pathways of the host cell and
establish an intracellular niche favorable to its development. An extensive network of interactions exists between
C. trachomatis and host proteins to facilitate bacterial attachment and entry and C. trachomatis development in
the host cell. C. trachomatis can interact with and modulate the activity of numerous cell surface receptors to promote attachment and entry into the host cell. EGFR is an
important cell surface receptor tyrosine kinase with a central role in cell growth, proliferation and migration [49].
The function of EGFR was studied in a number of bacterial and viral infections (e.g., C. pneumoniae, Pseudomonas
aeruginosa, Neisseria gonorrhoeae, HPV); however, it has
not been thoroughly investigated in relation to C. trachomatis pathogenesis. We provide here the first evidence
that C. trachomatis has the ability to upregulate EGFR activity in host cells and establish EGFR as a critical effector
molecule in the formation of chlamydial inclusions within
the host cells.
We demonstrate that C. trachomatis induces an increase
in EGFR phosphorylation and that inhibition of EGFR
phosphorylation or depletion of EGFR protein impairs C.
trachomatis attachment and its development in the host
cells. In 2008, Elwell et al. analyzed both PDGFRβ and
EGFR phosphorylation in HeLa cells infected with C. muridarum [19]. While there was an increased phosphorylation of PDGFRβ, a change in phosphorylation of EGFR

was not observed in this study. The discrepancy in results
could be due to differences in the time points (hpi) investigated, MOI and Chlamydia species. Our results are further supported by the EGFR-dependent increase in
phosphorylation of downstream targets like Akt, STAT5
and PLCγ1 in C. trachomatis infected cells. Phosphorylation of Akt during chlamydial infection is well documented [27-29] and previous studies reported that
activation of the PI3K/Akt pathway blocks the cytochrome
c release from the mitochondria and delays apoptosis
thereby promoting chlamydial growth and survival inside
the host cell [50]. The lack of Akt phosphorylation in
EGFR−/− cells demonstrates EGFR as the upstream regulator of Akt phosphorylation, which was not known before.
With respect to STAT5 activation, a recent report showed
that the interaction of EGFR with STAT5 in the nucleus
could lead to activation of Aurora-A gene expression [37],
and subsequent chromosomal instability. Interestingly, C.
trachomatis infection was previously linked to centrosome
defects [51,52]. Thus, a mechanistic connection could
exist between C. trachomatis-induced activation of EGFR
and STAT5 and the centrosome abnormalities observed in
C. trachomatis infections; this remains to be investigated.
In this study, we have followed-up on EGFR-dependent
activation of PLCγ1. It is well known that EGF binding to
EGFR results in activation of PLCγ1. The subsequent production of IP3 is linked to activation of IP3 receptor
(IP3R) and intracellular calcium mobilization [53]. There
is extensive evidence that links EGFR activation to this
process [43,46] and we demonstrate here that inhibition of
EGFR abrogates the C. trachomatis-induced increase in
intracellular calcium flux. Also, removal of calcium by
chelation resulted in marked reduction in the size and
number of chlamydial inclusion similar to EGFR inhibition. This is consistent with previous studies, which have
reported localization of intracellular calcium stores and
regulators of calcium release and uptake (IP3R and
SERCA2, respectively) in the vicinity of C. trachomatis inclusions and formation of immature inclusions upon inhibition of calcium binding proteins like calmodulin
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Figure 7 EGFR is required for the reorganization of F-actin at the periphery of chlamydial inclusions. (A-C) Organization of F-actin at the
chlamydial inclusion periphery. HeLa cells treated with (A) control siRNA, (B) EGFR siRNA or (C) Erlotinib, were infected with C. trachomatis for 24
h, fixed, and processed for confocal microscopy. F-actin was detected with Alexa Fluor 488-phalloidin (green) and chlamydial inclusions were
detected using anti-chlamydial LPS antibody (red). Note the distinct assembly of F-actin at the inclusion periphery in (A) which is altered upon
inhibition of EGFR (B and C). (D) HeLa cells treated with IgG or Cetuximab were infected with Ct for 24 h, fixed, and processed for confocal
microscopy. F-actin was detected with Alexa Fluor 488-phalloidin (green) and chlamydial inclusions were detected using anti-chlamydial LPS
antibody (red). Note the distinct assembly of F-actin at the inclusion periphery in IgG treated cells and the lack of it in Cetuximab treated cells.
Scale bar - 10 μm. (E) Organization of F-actin at the chlamydial inclusion periphery in MEFs EGFR+/+ and MEFs EGFR−/−. MEFs EGFR+/+ and MEFs
EGFR−/− were infected and processed as in (A). F-actin is noticeably rearranged at the chlamydial inclusion periphery in the MEFs EGFR+/+ but
not in the MEFs EGFR−/− cells.

[42,54]. However, the failure to restore C. trachomatis inclusion development by addition of a calcium ionophore
(e.g., Ionomycin) indicated that other EGFR-regulated processes might contribute to C. trachomatis inclusion development in conjunction with calcium.

C. trachomatis is known to utilize cytoskeletal elements like F-actin and intermediate filaments to form a
dynamically regulated scaffold that maintains the structural integrity of the chlamydial inclusions [18]. A unique
feature of EGFR that distinguishes it from PDGFRβ is its
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Figure 8 Co-localization of EGFR and F-actin at the periphery of C. trachomatis inclusion. (A) HeLa cells were infected with C. trachomatis
for 24 h, fixed and processed for confocal imaging to detect C. trachomatis (blue), F-actin (green) and EGFR (red). The merged image shows
co-localization of EGFR and F-actin as illustrated by the yellow signal. Dashed box represents the inclusion area, solid box represents area and
direction of intensity profile measurement in (C). Scale bars are 5 μm and 2 μm in whole cell and inclusion area images, respectively. (B) nMDP
color maps showing heat maps of co-localization areas in whole cell and inclusion area images. Both cell and inclusion boundaries show similar
evidence of co-localization ranging from moderate to intense. (C) Intensity profiles of C. trachomatis, EGFR, and F-actin from cell boundary to cell
boundary across the inclusion. EGFR and F-actin signals rise and fall in similar patterns along the inclusion boundary (located at approximately 6
μm and 18 μm on the x-axis) indicating co-localization in a similar manner as at the cell boundary (located at approximately 3 μm and 21 μm on
the x-axis). (D) Comparison of co-localization parameters between inclusion area images and non-inclusion area images (details in the legend for
Additional file 3: Figures S14-S20). All five parameters show significant increase of co-localization in inclusion areas compared with non-inclusion
areas. Data presented represent the mean ± standard deviation; n = 8 images within each subset, ***p < 0.001.

ability to regulate actin polymerization through its F-actin
binding domain. EGFR and F-actin interaction was previously reported to play an active role in EGFR internalization and has been proposed to localize EGFR signaling at

specific loci within the cell [45,55]. Our data show distinct
co-localization of EGFR with the F-actin ring around the
chlamydial inclusion and interruption in the formation of
F-actin rings around the chlamydial inclusions in both
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calcium depleted and EGFR inhibited cells. These results
are consistent with the function of PLCγ1 and calcium
mobilization in cytoskeletal remodeling [31,32]. Rho family
of small GTPases has also been reported to participate in
the EGFR-dependent regulation of cytoskeletal remodeling
[55] and previous findings have shown recruitment of these
molecules at the inclusion periphery [18] Therefore, EGFR
interaction with F-actin may function to nucleate the assembly of signaling protein complexes for cytoskeletal remodeling required for inclusion development.
EGFR-dependent regulation of F-actin and calcium release can affect inclusion formation at multiple stages of
C. trachomatis infection. First, it can have a direct effect
on the bacterial attachment and entry. Consistent with
this, our data indicate that EGFR inhibition significantly
impairs the bacterial attachment to the host cell surface
at a level comparable with inhibition of PDGFRβ. Recently, Molleken et al. demonstrated that EGFR inhibition
(by another EGFR tyrosine kinase inhibitor AG1478) reduced C. pneumoniae EB internalization to HEp-2 cells
but did not affect EB attachment [25]. The discrepancy
could be due to differences in the Chlamydia species, host
cell lines and the dose and type of EGFR inhibitors used in
these studies. Nevertheless, the defect in bacterial attachment seen in our studies could be due to the inability to
bind to EGFR and/or the defective EGFR signaling. Since
Erlotinib, as an EGFR tyrosine kinase inhibitor, does not
directly compete with C. trachomatis for binding to
EGFR, our results suggest that C. trachomatis attachment is not only mediated by its binding to EGFR, but
also facilitated by the downstream signaling events.
Early events of C. trachomatis infection (1–2 hpi) involve accumulation of tyrosine phosphorylated proteins
at the site of entry [16,17,56,57], cytoskeletal remodeling
and reorganization of microvilli at the cellular surface for
C. trachomatis uptake [58,59]. We propose that C. trachomatis-activated EGFR can trigger changes in cytoskeletal
rearrangement and microvilli extensions that favor C. trachomatis attachment and entry. Whether EGFR activation
is the direct result of EBs binding to the extracellular domain of EGFR or occurs indirectly (e.g., through activation
of Src tyrosine kinase), it remains to be investigated in future studies. Alternatively, reduced C. trachomatis attachment to Erlotinib-treated host cells could be due to
changes in EGFR subcellular localization or EGFR affinity
to its ligand. However, in our imaging studies, we did not
detect any significant changes in EGFR cell surface
localization in the presence of Erlotinib, consistent with
another report [60]. Although other EGFR tyrosine kinase
inhibitors (e.g. Gefitinib, AG1478) have been shown to
alter EGFR interaction with its ligand [61,62], whether Erlotinib could change the affinity of EGFR to its ligand remains to be investigated. However, the Molleken et al.
studies, which used AG1478 would suggest that this
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mechanism is unlikely and that the attachment of EBs to
host cell is impaired by inhibition of EGFR downstream
signaling. It should be noted that entry of C. trachomatis
in the host cell could use multiple routes. Our data supports this statement since independent inhibitions of either EGFR or PDGFRβ affect the bacterial attachment and
neither of the two receptors can compensate for the other.
The second stage at which EGFR can control the inclusion
development is at the local aggregation of C. trachomatis
inside the cell. In fact, experiments in which EGFR was
inhibited post chlamydial invasion, showed decreased
intracellular calcium (Additional file 2: Figure S10) as well
as numerous bacterial aggregates (Figure 5), perhaps stalled
at the stage of fusion of bacterial inclusions. As discussed
above, a number of studies have indicated a role of calcium
in aggregation of C. trachomatis and F-actin rearrangement
[32,54]. The EGFR-dependent regulation of calcium and Factin not only provides the dynamic structural scaffold for
the expanding inclusion but can also aid in the nutrient uptake required for replicating bacteria since the F-actin and
microtubules are known to be essential for vesicular trafficking and intracellular motility [63]. Interference with the
F-actin arrangements by inhibiting EGFR can therefore impair the maturation of chlamydial inclusions.

Conclusions
In summary, the studies included here show that chlamydial infection upregulates EGFR activity in host cells. This
results in activation of downstream effectors of EGFR such
as PLCγ1, Akt and STAT5. We demonstrate that EGFR
and EGFR-mediated signaling play a critical role in both
C. trachomatis attachment and development of C. trachomatis inclusions in host cells through mechanisms that involve EGFR-dependent regulation of calcium release, actin
cytoskeleton rearrangement, and EGFR co-localization
with F-actin at the inclusion periphery. These findings
shed light on the complexity of C. trachomatis-host cell
interactions, which when solved may open new venues to
treat C. trachomatis infections and C. trachomatis-associated diseases. These results form the basis of the model we
propose in Figure 9, which will be further evaluated in the
future. In this model, EGFR plays a key role in the early
and middle stages of C. trachomatis infection wherein the
EGFR mediated calcium signaling and F-actin remodeling
are central to the establishment of a successful C. trachomatis infection inside the eukaryotic cells. The model
shows the direct activation of EGFR by EBs binding, but as
discussed above other mechanisms are possible and warrant investigation.
Methods
Reagents

Antibodies were obtained from the following sources:
goat anti-chlamydial LPS, goat anti - C. trachomatis EB
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Figure 9 Proposed model of EGFR involvement at various stages of C. trachomatis infection. C. trachomatis infection induces EGFR
phosphorylation and activation of downstream targets like Akt, STAT5 and PLCγ1. The direct activation of EGFR by EBs binding to the extracellular
domain of EGFR is shown here but other indirect mechanisms of EGFR activation are possible as well. Activation of EGFR signaling can
upregulate host cell survival mechanisms and induce increased calcium mobilization. EGFR co-localization with F-actin is suggestive of a possible
direct role of EGFR in formation of F-actin rings at the periphery of inclusion. The increased calcium signaling can have several functions ranging
from cytoskeletal remodeling to recruitment of host proteins at the inclusion membrane. The EGFR-induced formation of F-actin ring and other
cytoskeletal elements at the inclusion periphery can further aid in inclusion expansion via vesicular trafficking and nutrient uptake.

(Meridian Life Sciences, Saco, ME, USA); FITC conjugated anti-chlamydial EBs (Fitzgerald, MA, USA), rabbit
anti-EGFR, rabbit anti-PLCγ1, rabbit anti-pPLCγ1, rabbit
anti-Stat5, rabbit anti-pStat5, rabbit anti-Akt, rabbit antipAkt, rabbit anti-pPDGFRβ (Y751), rabbit anti-EGFR
(Alexa Fluor 594 conjugate) and rabbit anti-β actin (Cell
Signaling, Danvers, MA, USA); rabbit anti-pEGFR (Y1173),
rabbit anti-PDGFRβ, mouse anti-chlamydial Hsp60 and
rabbit anti-mouse IgG HRP antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA, USA); rabbit anti-pEGFR
antibodies (Y845, Y992, Y1045, Y1148; Millipore, Temecula,
CA, USA); donkey anti-goat IgG H&L (Alexa Fluor 405)
(Abcam, Cambridge, MA, USA); anti-EGFR-Alexa Fluor
488 antibody (Millipore, Temecula, CA, USA), goat antirabbit IgG HRP, FITC-conjugated anti-rabbit antibody and
rhodamine red conjugated anti-goat secondary antibodies
(Jackson Laboratories, West Grove, PA, USA). EGFR siRNA

(human and mouse), PDGFRβ siRNA (human), control
siRNA and siRNA transfection reagents were obtained
from Santa Cruz Biotechnology, Santa Cruz, CA, USA
and Dharmacon USA. DMEM, DMEM (Ca++ free), FCS,
FBS and Alexa Fluor 488 phalloidin and Fluo-4 AM were
purchased from Invitrogen, Grand Island, NY, USA. Pathfinder Chlamydia Culture Confirmation System was purchased from BioRad, Hercules, CA, USA. HBSS and PBS
were purchased from Lonza, Walkersville, MD, USA. DEAE
dextran, BAPTA/AM, Ionomycin, and cyclohexamide were
purchased from Sigma Aldrich, St. Louis, MO, USA. Cell
Proliferation Kit I (MTT) and Fast Start Universal SYBR
green (Rox) were obtained from Roche, Indianapolis, IN,
USA. Erlotinib was purchased from Selleck Chemicals LLC,
Houston, TX, USA and Cetuximab was a kind gift from Dr.
Katerina Politi (Department of Pathology, Yale University).
Bicinchoninic acid (BCA) assay for protein quantification
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was purchased from Thermo Scientific, Rockford, IL, USA.
ECL Plus Western blotting detection reagent was purchased
from Perkin Elmer, Waltham, MA, USA.
Cell culture

Chlamydia trachomatis strain D, HeLa and NIH 3T3
were purchased from ATCC. Mouse embryonic fibroblasts (MEFs EGFR+/+ and EGFR−/−) were kindly provided by Dr. Jennifer Grandis (University of Pittsburg)
[64]. HeLa and MEFs were cultured using DMEM + 10%
FBS. NIH 3T3 cells were cultured in DMEM + 10% FCS.
All cell lines were maintained at 37°C and 5% CO2.
Propagation of Chlamydia and infections

Chlamydia trachomatis strain D (C. trachomatis) was
propagated in HeLa cells grown in complete DMEM
containing cyclohexamide (2 μg/ml). After 48 h, infected
cells were harvested in sucrose-phosphate-glutamate
(SPG) buffer, ruptured by vortexing with 3mm glass
beads. EBs were purified using previously described
methods [28]. The resulting bacterial pellet was resuspended in cold SPG buffer with a 21 to 22-gauge injection
needle and stored in aliquots at −80°C. For infection, chlamydial EBs were added to cells in monolayer (80% confluence) at a multiplicity of infection (MOI) of 2–10 for all
studies included here. Centrifugation was not used during
the infection.
Immunoblotting

Cells were harvested and lysed in modified RIPA buffer
(50 mM Tris, 150 mM NaCl, 1% sodium deoxycholate,
1% NP-40, 1 mM sodium fluoride) supplemented with
protease inhibitor cocktail and phosphatase inhibitor
tablet (Roche). For Western blotting of C. trachomatis
antigens, the C. trachomatis-infected cells were lysed in
20 mM HEPES buffer (pH 8.0) containing 8 M urea supplemented with protease inhibitors. Cell lysates were incubated on ice for 1 h and then sonicated briefly. The
soluble protein fraction was collected by centrifugation
at 10,000 rpm. Total protein was estimated using the
BCA method and equal amounts of proteins (10–20 μg)
were processed for immunoblotting. Proteins were resolved on 10% SDS polyacrylamide gel and transferred
onto a nitrocellulose membrane. The blot was blocked
using 3% BSA and incubated with the indicated antibodies. ECL was used to detect the proteins according to
the manufacturer’s instructions.
siRNA transfections

Cells were grown to 60% confluency followed by transfection with EGFR siRNA/PDGFRβ siRNA or control
siRNA (Santa Cruz/Dharmacon) according to manufacturer's protocol. After 24 h, transfected cells were replated for
a second round of transfection. After another 24 h,
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cells were infected with C. trachomatis and incubated
for different time intervals (siRNA was maintained
during the infection) according to the experimental
design and were either stained for analyzing the inclusion development or prepared for Western blot
analysis.
EGFR inhibitor treatment

Erlotinib and Cetuximab treatments were used for EGFR
inhibition. The cells were pretreated with Erlotinib (25
μM) for 2 h and then infected with C. trachomatis. For
Cetuximab treatment, cells were treated with 20 μg/ml
drug for 2 h in DMEM +0.1% FBS followed by C. trachomatis infection. The inhibitor concentration was maintained during the infection. In certain experiments in
which protein phosphorylation was investigated (Figure 1B,
D, F, G, Figures 3, 4, and Additional file 1: Figure S2) the
cells were serum starved overnight before drug treatment
and C. trachomatis infection. DMSO was used as the vehicle control for Erlotinib and IgG was used as control
treatment for Cetuximab. Infected samples were used
either for Western blotting or confocal imaging as described
below. In another set of experiments the cells were infected with C. trachomatis followed by addition of Erlotinib at 2.5, 5 and 18 hpi. The total time for C. trachomatis
infection was 24 h after which the samples were used for
Western blotting or confocal imaging. Control experiments. Chlamydial EBs were mixed with complete DMEM
(DMEM + 10% FBS) containing either 25 μM Erlotinib,
20 μg/ml Cetuximab or DMSO and incubated for 2.5 h
at 37°C, centrifuged at 16,000 rpm at 4°C for 30 minutes. EBs’ pellets were washed and resuspended in
SPG buffer and used for subsequent HeLa cell infection.
At 24 hpi cells were lysed for Western blotting of chlamydial Hsp60 antigen.
Inside out staining

Differential staining of external and internalized bacteria
was performed as described previously and using three
independent studies [19]. Briefly, cells were grown overnight in 2-well Lab-Tek chamber slides and treated with
either EGFR inhibitors or siRNA as described above and
subsequently infected with Chlamydia for 2.5 h at 37°C
to allow for bacterial attachment and internalization. For
blocking EGFR with Cetuximab, cells were preincubated
with Cetuximab or control IgG for 2 h before addition
of bacteria. Infected cells were washed five times in PBS
and fixed in 1% paraformaldehyde (PFA). After fixation,
cells were blocked in 5% BSA for 1 h and then incubated
with FITC-conjugated antibody against chlamydial EBs
for 1 h to stain external EBs. Cells were then permeabilized with 0.1% Triton X-100, blocked again, and incubated with antibody against chlamydial LPS followed
by incubation with rhodamine-conjugated anti-goat
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antibody to stain intracellular and extracellular EBs. Imaging was performed using confocal microscopy (Carl
Zeiss, Germany). The quantification for the inside out
experiments was performed manually based on the
number of attached EBs observed per infected cell.
The statistical analysis was based on imaging data
collected from fifteen fields containing 3–10 cells per
field as described below under “Image acquisition and
statistical analysis”.
Immunofluorescence

Cells were infected with C. trachomatis as described
above. The cells were washed 5 times with PBS and fixed
at either 2.5 hpi or 24 hpi with 4% PFA for 10 min and
blocked with 5% BSA for 1 h. After washing with TBS
(50 mM Tris.HCl, pH 7.4 and 150 mM NaCl) the cells
were permeabilized for 15 min with 0.1% TritonX100
and again washed with TBS followed by incubation with
the indicated primary antibodies overnight. The cells
were washed three times (10 min each) with TBS and incubated with appropriate secondary antibodies and
Alexa Fluor 488-phalloidin (1:40 dilution in PBS) for 1
h. After repeated washings, the coverslips were mounted
and analyzed using Zeiss LSM 510 or 710 laser scanning
confocal microscope. For the studies shown in Figure 1A,
C. trachomatis inclusions were stained using the Pathfinder Chlamydia Culture Confirmation System (BioRad,
Hercules, CA, USA). At 24 h post C. trachomatis infection, cells were fixed with methanol for 10 min at room
temperature and stained with the FITC conjugated pathfinder anti-chlamydial mAb according to the manufacturer’s protocol (Bio-Rad, Hercules, CA). For the colocalization studies, 30,000 HeLa cells were seeded into
EZ slide 4-well glass (Millipore, Temecula, CA, USA)
and infected with C. trachomatis as described above for
2.5 h the next day. Cells were fixed 24 h later in 4% formaldehyde in PBS for 15 min, permeabilized in 0.1%
Triton X-100 for 10 min, and blocked in 1% BSA for 1 h
at room temperature. Then the cells were incubated
with anti-EGFR rabbit mAb (Alexa Fluor 594 conjugate,
Cell Signaling, Danvers, MA, USA) overnight at 4°C,
followed by incubation with Alexa Fluor 488 Phalloidin
(Invitrogen, Grand Island, NY, USA) for 1 h at room
temperature. The slides were mounted with Fluoromount mounting medium (Sigma Aldrich, St. Louis,
MO, USA), sealed, and examined using Zeiss 710 laser
scanning confocal microscope.
Intracellular calcium staining

Cells were washed with calcium free incomplete DMEM
and incubated with 2 μM Fluo-4 AM diluted in Ca2++ free
incomplete DMEM at 37°C for 30 min. The cells were
then washed with Ca2++ free HBSS and analyzed for calcium levels using Olympus IX71 fluorescence microscope.
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BAPTA/AM and Ionomycin treatment

Monolayers of HeLa cells were washed with PBS and replaced with calcium free DMEM +1% FBS and pretreated for 1 h with BAPTA/AM (15 μM) followed by
C. trachomatis infection for 24 h. BAPTA/AM concentration was maintained during the C. trachomatis infection. The control cells were treated with DMSO (<0.1%)
followed by 24 h of C. trachomatis infection. In another
set of experiments, HeLa cells were infected with C. trachomatis followed by addition of BAPTA/AM (15 μM)
or DMSO at 2 or 5 hpi. The total time for C. trachomatis infection was 24 h. To induce mobilization of calcium
from intracellular stores to the cytoplasm, cultured cells
were pretreated for 1 h with 1 μg/ml Ionomycin before
chlamydial infection. C. trachomatis-infected cells were
washed three times with PBS after 24 hpi and processed
for immunofluorescence as described above.
Cell proliferation assay

To ensure that the dose of Erlotinib (25 μM) provided
maximal inhibition without affecting cell viability, MTT
assays were performed. HeLa cells were cultured for 24
h, treated with 25 μM Erlotinib and incubated at 37°C,
5% CO2 for 24 h. After washing the cells, the procedure
for cell viability assay was followed as per manufacturer’s
instructions (Roche).
Transmission electron microscopy

HeLa cells were infected with C. trachomatis as described above. Twenty-four hours post chlamydial infection the cells were washed with PBS and fixed with 2.5%
glutaraldehyde in 0.1 N Millonig’s buffer (pH 7.2) for 1 h
at room temperature. The cells were then washed and
post-fixed for 1 h in 1% osmic acid in 0.1 N Millonig’s
buffer followed by 1 h treatment with 1% uranyl acetate.
A graded ethanol series (25%, 50%, 70-75%, 90-95% and
100%) was used to dehydrate the cells prior to embedding
in Spurr’s resin. Thin sections were then cut with a Reichert
ultracut E microtome and stained with 1% uranyl acetate
and Reynold’s lead citrate solutions, followed by the analysis
using 80 kV Tecnai Spirit BioTwin transmission electron
microscope.
Image acquisition and statistical analysis

Images of stained cells were acquired in a Z-series on a
Zeiss LSM 710 AxioObserver Z.1 inverted laser scanning
confocal microscope using a Zeiss Plan-Apochromat 63×/
1.3 water-immersion objective with 3× digital zoom at the
Wake Forest University Microscopic Imaging Core Facility
and Confocal Microscopy Center. Lasers of 405 nm
(25 mW diode), 488 nm (35 mW Argon laser), and 594
nm (2 mW He/Ne laser) were used to illuminate the samples and images were captured using a R6357 photomultiplier tube (Hamamatsu Photonics, Hamamatsu City,
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Japan) with a pixel dwell time of 0.79 μs. Final image magnification at the time of image capture was 1,890×, with
each voxel representing 0.02 μm × 0.02 μm × 0.39 μm. A
pinhole of 53.88 μm (~1 Airy unit for the red channel)
was used for all color channels of all images. All images
were captured at 2048 × 2048 pixels, saved in 8-bit .lsm
image format, and converted to .tif format for analysis
in the MacBiophotonics ImageJ package (McMaster
University Biophotonics Facility, Hamilton, Ontario, CA).
A median filter of 7 × 7 pixels was applied to EGFR images
using Zeiss Zen 2011 Blue Edition (Carl Zeiss Microscopy
GmbH, Göttingen, Germany) to reduce background noise.
Co-localization of each image was determined using eight
independent techniques. Standard overlays and intensity
profile data were generated using Zen 2011, while six different co-localization analysis algorithms were performed
using the JACoP [48] and Colocalization Colormap [47]
plugins for ImageJ (National Institutes of Health, USA).
ImageJ was used for quantification of the Western blots,
counting and estimation of chlamydial inclusion size and
for the counting of the bound and internalized EBs (inside
out studies). To define the chlamydial inclusion number
and size at least fifteen random fields were analyzed for
each result. The number of inclusions was calculated per
105 cells and expressed as a percentage of the respective
controls. Similarly, fifteen random fields (3–10 cells per
field) were used for the inside out experiments. All results
are presented as mean ± SEM. t-test was used for comparisons and calculating the level of significance using SigmaPlot version 12.0.

Additional files
Additional file 1: Control experiments to support studies in
Figures 1, 2, 3, 4, 5, 6 and 7.
Additional file 2: Supplementary data to support the function of
calcium in Ct infection.
Additional file 3: Description of methods used for co-localization
analysis and additional co-localization figures.
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